Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26352875 | 1.00 | CA1 (0.32) | CA1CA2CTSSCTSK | |
| SCHEMBL10061083 | 1.00 | CA1 (0.32) | CA1CA2CTSSCTSK | |
| SCHEMBL14347557 | 0.84 | — | — | |
| SCHEMBL7802720 | 0.83 | HDAC7 (0.34) | CA1CA2CTSSCTSK | |
| SCHEMBL12250669 | 0.83 | HDAC7 (0.34) | CA1CA2CTSSCTSK | |
| SCHEMBL13227959 | 0.82 | TGFBR1 (0.31) | — | |
| SCHEMBL16510366 | 0.82 | TGFBR1 (0.31) | — | |
| SCHEMBL13631881 | 0.82 | TGFBR1 (0.31) | — | |
| SCHEMBL14347307 | 0.80 | GRN (0.33) | — | |
| SCHEMBL18964003 | 0.80 | HSP90AA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210060121-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING THEM | VERSITECH LIMITED (CN) | 2021-03-04 | — | — | US | disclosed |
| US-20210008099-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEATTLE GENETICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008099-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | CA1 4287/4885CA2 3971/4885CTSS 1713/4885 |
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | CA1 3103/4885CA2 2094/4885CTSS 2829/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | CA1 1424/4885CA2 3074/4885CTSS 2099/4885 |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | MSN, AURKA, AURKC | CA1 4287/4885CA2 3971/4885CTSS 1713/4885 |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | CA1 4287/4885CA2 3971/4885CTSS 1713/4885 |
| US-20210060121-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING THEM | VIP, TLR5, TREH | CA1 4864/4885CA2 4413/4885CTSS 1813/4885 |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | CA1 2535/4885CA2 2170/4885CTSS 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.